[1] |
Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu.
Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021
[J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
|
[2] |
Yang Ziyi, Chen Suting.
Research progress on bedaquiline resistance and drug resistance diagnosis
[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 374-379.
|
[3] |
Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan.
Safety of extended delamanid use in drug-resistant tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
|
[4] |
Xu Zian, Pu Feifei, Feng Jing, Xia Ping.
Research progress of high-throughput sequencing technology in the diagnosis and treatment of osteoarticular tuberculosis
[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 224-230.
|
[5] |
Li Xueqiu, Liu Qun, Tang Ke, Wu Di.
Analysis of mortality trend of pulmonary tuberculosis cases with an age-period-cohort model in Guangzhou City, 2011—2020
[J]. Chinese Journal of Antituberculosis, 2025, 47(1): 44-50.
|
[6] |
Geng Zimei, Wang Chaohong, Long Sibo, Zheng Maike, Shi Yiheng, Sun Yong, Zhao Yan, Wang Guirong.
Analysis of bacteriological positivity and rifampicin resistance in patients with severe pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1050-1055.
|
[7] |
Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi.
Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023
[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076.
|
[8] |
Yang Liangzi, Zhang Peize, Lu Shuihua.
Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876.
|
[9] |
Xue Yi, Liang Qian, Qi Haoran, Liang Ruixia, Huang Hairong.
Reliability analysis of rifampicin-resistance detected by different diagnostics as a predictor for multidrug-resistant tuberculosis
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 892-896.
|
[10] |
Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei.
Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950.
|
[11] |
Gao Lei, Liang Yaxue, Liu Shengsheng, Wang Hua.
Analysis of treatment outcomes and influencing factors in 144 elderly patients with rifampicin drug-resistant pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2024, 46(7): 799-807.
|
[12] |
Zhang Hongtai, Ren Yixuan, Hu peilei, Wang Nenhan, Li Jie, Tian Lili, Zhao Yanfeng, Chen Shuangshuang, Li Chuanyou.
Comparison of microbiota diversity in the sputum of pulmonary tuberculosis patients with rifampicin resistance or sensitivity
[J]. Chinese Journal of Antituberculosis, 2024, 46(6): 625-633.
|
[13] |
Du Yuhua, Feng Yajuan, Lei Yu, Lai Keng, He Weiyun.
Analysis of the detection and treatment of rifampicin-resistant pulmonary tuberculosis patients in Guangzhou during the “12th Five-Year Plan” and “13th Five-Year Plan” periods
[J]. Chinese Journal of Antituberculosis, 2024, 46(6): 678-686.
|
[14] |
Ye Xinchun, Liu Saiduo, Cheng Fang, Jiang Xiangao, Ning Hongye, Wu Zhengxing, Zhou Yueying, Qiu Chaochao, Pan Ning, Shi Jichan.
Risk factors of latent tuberculosis infection among close contacts of drug-resistant pulmonary tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2024, 46(5): 525-530.
|
[15] |
Bao Xundi, Liang Suo, Li Jun, Ye Qian, Wu Dandan, Wang Shu, LI Yue, Ding Yunsheng, Liu Jie.
Analysis of Mycobacterium tuberculosis drug resistance monitoring in Anhui Province from 2016 to 2022
[J]. Chinese Journal of Antituberculosis, 2024, 46(5): 531-537.
|